The dopamine D1 agonist SKF 81297 and th
✍
R. J. Vermeulen; Dr. B. Drukarch; M. C. R. Sahadat; C. Goosen; E. C. Wolters; J.
📂
Article
📅
1994
🏛
John Wiley and Sons
🌐
English
⚖ 902 KB
## Abstract At present, the pharmacotherapy of Parkinson's disease (PD) consists mainly of L‐dihydroxyphenylalanine (L‐DOPA) and/or dopamine D~2~ receptor agonist. However, in general the clinical efficacy of D~2~ agonists is less than that of L‐DOPA. Therefore, attention is being focussed on the r